Protein Kinase Inhibitors: all 15,766 studies that test it

Page 5 of 158. Open to participants first (2,605), then studies with results posted, then the rest; newest registration first within each.

• A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of RecurrenceRecruitingNCT07475026Phase 3
• Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung CancerRecruitingNCT07473128Phase 3
• SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell CarcinomaNot yet recruitingNCT07470840Phase 2
• Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid CancerNot yet recruitingNCT07470489Phase 2
• Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic CancerNot yet recruitingNCT07469956Phase 2
• A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsRecruitingNCT07469891Phase 1
• An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell CarcinomaRecruitingNCT07469683Phase 2
• Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line TreatmentRecruitingNCT07467330Phase 3
• A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)RecruitingNCT07465757Phase 2
• CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT07464951Phase 1
• SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric CancerRecruitingNCT07464756Phase 2
• Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingNCT07463677Phase 2
• MRD-guided Maintenance Post-HCT: Gilteritini vs SorafenibRecruitingNCT07463651Phase 3
• Study of LUT017 Gel to Improve Healing of Skin Wounds After Removal of Benign Lesions in Healthy AdultsNot yet recruitingNCT07463378Phase 1
• Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatmentNot yet recruitingNCT07460206Phase 2
• Therapy for Advanced NSCLC With EGFR 19delins MutationNot yet recruitingNCT07458919Early Phase 1
• Remibrutinib Open Label Roll-over Post-trial Access ProtocolRecruitingNCT07456891Phase 3
• Study of the Safety and Usefulness of Liposomal Curcumin in Multiple MyelomaRecruitingNCT07456605Phase 1
• Efficacy and Safety of Ivarmacitinib Monotherapy in the Treatment of csDMARDs-IR Rheumatoid ArthritisNot yet recruitingNCT07452445Phase 4
• Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's ArteritisNot yet recruitingNCT07451665Phase 4
• Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical TrialNot yet recruitingNCT07449910Phase 2/3
• Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant MelanomaRecruitingNCT07449754Phase 2
• Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZLRecruitingNCT07448324Phase 2
• Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.RecruitingNCT07448116Phase 1/2
• Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With CytopeniasNot yet recruitingNCT07447817Phase 2
• Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)RecruitingNCT07447076Phase 2
• FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal CancerNot yet recruitingNCT07446465Phase 4
• Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal MalignanciesNot yet recruitingNCT07446270Phase 2
• A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low ExpressionNot yet recruitingNCT07446049Phase 2
• Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal AdenocarcinomaNot yet recruitingNCT07445295Phase 3
• RWS of Tunlametinib in NRAS-Mutant Advanced MelanomaRecruitingNCT07445022Phase 4
• A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue SarcomasRecruitingNCT07444619Phase 1
• Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.RecruitingNCT07443397Phase 3
• A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Intermediate to High Risk MyelofibrosisRecruitingNCT07443306Phase 2
• Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZLRecruitingNCT07441993Phase 2
• Study to Evaluate Soquelitinib in Participants With Moderate to Severe ADRecruitingNCT07441395Phase 2
• Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases CancerEnrolling by invitationNCT07441369Phase 2
• DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.RecruitingNCT07440290Phase 2/3
• Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid LeukemiaRecruitingNCT07439211Phase 1
• Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy VolunteersNot yet recruitingNCT07438886Phase 1
• Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic CancerRecruitingNCT07436741Phase 3
• Rapamycin Dose-Ranging Efficacy Study in Port Wine StainsNot yet recruitingNCT07436611Phase 2
• Curcumin in Critically Ill Patients With SepsisRecruitingNCT07436130Not applicable
• Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)Not yet recruitingNCT07435584Phase 1/2
• PH 2 Pemigatinib in SDH-deficient GISTRecruitingNCT07434843Phase 2
• A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICCNot yet recruitingNCT07432568Phase 2
• Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell HistiocytosisRecruitingNCT07431060Not applicable
• Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibRecruitingNCT07428707Early Phase 1
• A Study of Zanzalintinib in Participants With Recurrent or Progressive MeningiomaRecruitingNCT07428616Phase 2
• Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and AbemaciclibNot yet recruitingNCT07428018Phase 2
• Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast CancerRecruitingNCT07427394Phase 2
• FLT3-ITD Targeted Therapy in Fit AML PatientsNot yet recruitingNCT07425808Phase 2/3
• Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)RecruitingNCT07424222Phase 1
• A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLCNot yet recruitingNCT07418879Not applicable
• Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular LymphomaRecruitingNCT07418190Phase 2
• Tuvusertib in Astrocytoma With ATRX MutationRecruitingNCT07417761Phase 2
• Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 AmplificationRecruitingNCT07417501Phase 2
• Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System LymphomaRecruitingNCT07416890Phase 2
• Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung CancerRecruitingNCT07415005Phase 2
• Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line ChemotherapyRecruitingNCT07414758Phase 3
• RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-PositiveRecruitingNCT07413939Phase 2/3
• ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With RadiotherapyNot yet recruitingNCT07410611Phase 2
• Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast CancerNot yet recruitingNCT07410559Phase 2
• PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.RecruitingNCT07410520Phase 2
• A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLRecruitingNCT07409428Phase 3
• Adjuvant Intensification for LARNot yet recruitingNCT07407517Phase 3
• VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AMLNot yet recruitingNCT07407140Phase 3
• KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)RecruitingNCT07406633Phase 2
• Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)Not yet recruitingNCT07406204Phase 4
• A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast CancerRecruitingNCT07405801Phase 2
• Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)RecruitingNCT07405164Phase 3
• A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's DiseaseRecruitingNCT07403968Phase 2
• Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant ChemotherapyRecruitingNCT07400523Phase 3
• Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of TherapyNot yet recruitingNCT07400250Phase 2
• Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal CancerRecruitingNCT07398326Phase 2
• Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have ThrombocytopeniaRecruitingNCT07394153Phase 2
• Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast CancerRecruitingNCT07393425Phase 2
• Open-Label, Long-Term, Extension Study of Infigratinib in Children With HypochondroplasiaEnrolling by invitationNCT07393373Phase 2
• A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast CancerNot yet recruitingNCT07393321Phase 3
• A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.RecruitingNCT07392736Phase 1/2
• Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric CancerRecruitingNCT07392346Phase 2
• Zanubritnib and Anti-MAG NeuropathyRecruitingNCT07392229Phase 2
• A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based TreatmentNot yet recruitingNCT07392060Phase 3
• 5G-PEARL: Paxalisib in Malignant Brain TumoursRecruitingNCT07391215Phase 1/2
• Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLCNot yet recruitingNCT07388875Phase 2
• Effectiveness of Genistein in Mild Cognitive ImpairmentNot yet recruitingNCT07385937Not applicable
• Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal CarcinomaNot yet recruitingNCT07385079Phase 3
• QL1706 Plus Lenvatinib in Previously Treated Penile CancerRecruitingNCT07384416Phase 2
• A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid TumorsRecruitingNCT07383506Phase 1
• Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 SubtypeNot yet recruitingNCT07382687Phase 3
• A Clinical Study on the Efficacy and Safety of Ivarmacitinib in Preventing aGVHD After HLA-matched TransplantationNot yet recruitingNCT07381114Phase 1/2
• Evaluation of the Pharmacokinetics of Curcumin Capsules in Healthy HumanNot yet recruitingNCT07379177Not applicable
• Therapeutic RSK1 Targeting in Myeloid MalignanciesRecruitingNCT07379125Phase 1
• Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic HepatitisRecruitingNCT07378761Phase 2
• Systematic Approach for Children With Orbital Malformation With Sirolimus UseRecruitingNCT07378657Phase 3
• A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT07377578Phase 3
• Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line InductionNot yet recruitingNCT07376499Phase 2
• A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib MonotherapyRecruitingNCT07375316Phase 2
• A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib TabletRecruitingNCT07374224Phase 1
• Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell LymphomaRecruitingNCT07371923Phase 2

← Protein Kinase Inhibitors overview